China’s brain-computer interface industry is entering a decisive phase, as startups move rapidly from laboratory research into large-scale commercialization backed by coordinated state policy and expanding clinical infrastructure.
Neuralink has often framed itself as pioneering the field globally, yet Chinese companies are increasingly positioning themselves as serious contenders in both implantable and noninvasive BCI technologies.
Phoenix Peng, co-founder of NeuroXess and founder of ultrasound-focused Gestala, argues that neuroscience and artificial intelligence are converging into a single transformative industry with long-term global impact.
“I have always maintained that neuroscience and AI are two sides of the same coin,” Peng said. “They are destined for deep integration, realizing direct high-bandwidth connections between the human brain and AI. BCI will serve as the ultimate bridge between carbon-based and silicon-based intelligence. While this may sound distant, it represents an unimaginably vast market in the future.”
Policy And Clinical Infrastructure Drive Momentum
Beijing’s national roadmap, issued in 2025 by multiple ministries, sets clear milestones for technical breakthroughs by 2027 and a complete industrial supply chain by 2030, signaling sustained government commitment.
Provincial governments including Sichuan, Hubei, and Zhejiang have already introduced medical pricing standards for BCI services, accelerating their pathway into China’s national insurance reimbursement framework.
In December, authorities unveiled a 11.6 billion yuan brain science fund to support companies from early-stage research through commercialization, reinforcing investor confidence and cross-department alignment.
Peng attributes China’s rapid development to four pillars: policy coordination, access to vast clinical trial populations, manufacturing depth across semiconductors and medical hardware, and strong state-backed investment flows.
China’s centralized health insurance system also allows approved devices to reach patients faster than in markets where private insurers must independently authorize reimbursement decisions.
Researchers have completed the country’s first fully implanted wireless BCI trial, enabling a paralyzed patient to control devices without external hardware, marking only the second such procedure worldwide.
Investment Surges And Expanding Competition
Recent fundraising rounds underscore investor enthusiasm, with StairMed Technology raising 350 million yuan in early 2025 while BrainCo prepares for a Hong Kong listing after securing substantial capital.
China’s BCI market is projected to exceed $530 million in 2025, with long-term estimates suggesting dramatic expansion by 2040 as medical applications scale nationwide.
Invasive And Noninvasive Technologies Compete
The industry currently follows two primary technological paths, with invasive systems implanting electrodes directly into the brain for high-precision neural signals while noninvasive headsets prioritize safety and ease of use.
Emerging approaches including ultrasound-based interfaces are attracting attention for treating chronic pain, stroke, and depression without requiring surgery, broadening patient acceptance.
Gestala expects to introduce its first-generation product by the third quarter, with early trials indicating a 50% reduction in pain scores lasting up to two weeks.
As regulators refine approval frameworks and strengthen data oversight, industry insiders expect tighter controls over invasive devices while creating smoother pathways for noninvasive solutions.
Over the next five years, China’s regulatory alignment with international standards is anticipated to deepen, positioning domestic firms to compete directly with leading U.S. players in a rapidly maturing global market.
